In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs).
Increase in incidence of chronic diseases, coupled with need for rapid diagnostic techniques, is contributing to the increase in adoption of ISH.

Market Analysis and Insights: Global In Situ Hybridization (ISH) Market
The global In Situ Hybridization (ISH) market size is projected to reach US$ 1290.1 million by 2027, from US$ 968.1 million in 2020, at a CAGR of 4.1% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global In Situ Hybridization (ISH) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global In Situ Hybridization (ISH) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global In Situ Hybridization (ISH) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global In Situ Hybridization (ISH) market.

Global In Situ Hybridization (ISH) Scope and Market Size
In Situ Hybridization (ISH) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global In Situ Hybridization (ISH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Instruments
Kits & Probes
Software
Services

Segment by Application
Cancer
Cytogenetics
Developmental Biology
Infectious Diseases
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Thermo Fisher Scientific
Leica BiosystemsNussloch GmbH
BIOVIEW
Agilent Technologies
Merck KGaA
PerkinElmer Inc.
Bio-Rad Laboratories Inc.
NeoGenomics Laboratories Inc.
Advanced Cell Diagnostics Inc.
Oxford Gene Technology